MEBIAS holds a game-changing platform to discover next generation, pathway-selective GPCR drugs devoid of on-target side effects once thought to be unavoidable G-protein Coupled Receptor (GPCR) therapeutics comprise ~30% of current prescribed drugs. By developing pathway-selective/biased drugs within well-understood mechanisms, the significant on-target adverse effects can be alleviated. Cell-based assays alone are inadequate to identify biased drugs. Mebias’ understanding of protein dynamics of GPCRs offers a unique advantage. Given our experience and access to two key technologies – native GPCR purification and protein nuclear magnetic resonance – our approach offers resolution to identify biased agonists that is lacking in other methodologies. We have delivered a series of biased mu opioid receptor scaffolds among which is an NME-stage compound. The Mebias platform significantly decreases the time and costs to deliver optimized leads; our biased mu-opioids were designed within one year. The pathway-selective GPCR landscape is wide open. Our initial areas of focus are CNS/Pain, Metabolic, and Inflammatory related disorders. Expertise / Assets • Rapid identification and optimization of IND candidates devoid of on-target adverse effects, enabled by a fully validated assay suite which correlates ligand-induced dynamic conformation of GPCR to pathway specific signaling • Differentiated mu-opioid receptor pre-development candidates for the treatment of neuropathic and nociceptive pain (respiratory depression/GI motility/tolerance), e.g. MEB-4906 Business Proposal • Seeking co-development and/or license our mu-opioid drug candidates (one near IND ready) • Research funding/collaboration for lead discovery of additional targets in selected disease areas